SavedAdd your journal

Journals / Gazi Medical Journal / 2013 / Cilt: 24 - Sayı: 3

Tip 2 diyabetli hastalarda serum paraoksonaz düzeyleri ve pon1(192) polimorfizmi

Serum paraoxonase levels and pon1(192) polymorphism in type 2 diabetes mellitus patients

Ahmet ÖZAYDIN
Müjgan CENGİZ
Sanem GÖKÇEN
Pages
70–73
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

PON1192 RR homozygotes had significantly higher PON activity than QR and QQ genotypes among control and type 2 diabetes patients (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Paraoxonase-1 (PON1) is an HDL-associated enzyme implicated in the pathogenesis of atherosclerosis by protecting lipoproteins against peroxidation.
📊
Key Findings & Data:PON1 has two genetic polymorphisms both due to amino acid substitution, one involving glutamine and arginine at position 192 and the other leucineand methionine at position 55.
💡
Conclusion & Impact:PON1192 RR homozygotes had significantly higher PON activity than QR and QQ genotypes among control and type 2 diabetes patients (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Paraoxonase-1 (PON1) is an HDL-associated enzyme implicated in the pathogenesis of atherosclerosis by protecting lipoproteins against peroxidation. PON1 has two genetic polymorphisms both due to amino acid substitution, one involving glutamine and arginine at position 192 and the other leucineand methionine at position 55. Our study aimed to compare the effect of PON192 polymorphism and PON1 activity in patients with type 2 diabetes mellitus (T2DM) and non-diabetic controls. Material and Methods: 50 patients with T2DM and 30 non-diabetic controls were included in this study. The PON192 polymorphism was studied by polymerase chain reaction/restriction fragment length polymorphism (PCR/RFLP). Paraoxonase activity was measured by spectrophotometric method. Results: The frequencies of the QQ, QR and RR genotypes were found as 36.5 and 14% in type 2 diabetes patients and 26.67, 46.66, 26.67% in control subjects, respectively. The paraoxonase activity was detected at lower levels in diabetics (102.0 ±38.9) than in control subjects (158.1±63.7). PON1192 RR homozygotes had significantly higher PON activity than QR and QQ genotypes among control and type 2 diabetes patients (p

Özet

Amaç: Paraoksonaz-1 (PON1), peroksidasyona karşı lipoproteinleri koruyarak aterosklerozun patogenezinde rol oynayan HDL ile ilişkili bir enzimdir. PON1in, biri 192. Pozisyonda glutamin ve arginin; diğeri de 55. Pozisyonda lösin ve metyonin olmak üzere her ikisi de iki aminoasit yer değişiminden dolayı olan iki genetik polimorfizmi vardır. Çalışmamız, tip 2 diyabetes mellituslu (T2DM) hastalarda ve diyabetik olmayan kontrollerde PON192 polimorfizmi ve PON1 aktivitesinin etkisini karşılaştırmayı amaçlamıştır. Gereç ve yöntemler: Bu çalışmaya, 50 T2DM hasta ve 30 diyabetik olmayan kontrol alınmıştır. PON192 polimorfizmi, polimeraz zincir reaksiyonu/restriksiyon parça uzunluk polimorfizmi (PCR/RFLP) ile çalışılmıştır. Paraoksonaz aktivitesi, spektrofotometrik yöntemle ölçülmüştür. Bulgular: QQ, QR ve RR genotiplerinin sıklıkları tip 2 diabetli hastalarda sırasıyla %36, %50 ve %14, kontrol deneklerde ise %26.67, %46.66 ve %26.67 olarak bulunmuştur. Paraoksonaz aktivitesi, kontrol deneklerine (158.1±63.7) göre diyabetiklerde (102.0 ±38.9) daha düşük saptanmıştır. Kontrol ve tip 2 diabetli hastalar arasında PON1192 RR homozigotlar, QR ve QQ genotiplere göre anlamlı derecede daha yüksek PON aktivitesine sahipti (p

🔖

Cite This Article

ÖZAYDIN, A., CENGİZ, M., GÖKÇEN, S. (2022). Tip 2 diyabetli hastalarda serum paraoksonaz düzeyleri ve pon1(192) polimorfizmi. Gazi Medical Journal, Cilt: 24 - Sayı: 3, 70–73. https://ajindex.com/articles/520145

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Mackness MI, Durrington PN. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995;115:243–53
  2. Costa LG, Furlong CE, editors. Paraoxonase (PON1) in health and disease basic and clinical aspects. Norwell, MA: Kluwer Academic publishers; 2002; 165-168
  3. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996;7: 69-76
  4. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of human serum paraoxonase activity polymorphism. NatGenet 1993,3:73-6
  5. Li HL, Liu DP, Liang CC. Paraoxonase gene polymorphisms, oxidative stress, and diseases. J Mol Med 2003; 81: 766-9
  6. Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraoxonase (PON1) activity. BiochemPharmacol 2005; 69: 541-50
  7. Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase.Gen Pharmacol 1998; 31: 329-36
  8. Boemi M, Leviev I, Sirolla C, Pieri C, Marra M, James RW. Serum paraoxonase is reduced in type 1 diabetic patients compared to nondiabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis 2001; 155: 229-35
  9. McElveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem 1986;32: 671-3
  10. Agachan B, Yilmaz H,Karaali Z, Isbir T. Paraoxonase (PON1) 55 and 192 polymorphism and its relationship to serum paraoxonase activity and serum lipids in Turkish patients with non-insulin dependent diabetes mellitus. Cell Biochem Funct 2004;22:163-8
  11. Mackness B, Mackness M. Paraoxonase 1: biochemistry and contribution to atherosclerosis. International Congress Series 2004;1262:91-4
  12. Ikeda Y, Inoue M, Suehiro T, Arii K, Kumon Y, Hashimoto K. Low human paraoxonase predicts cardiovascular events in Japanese patients with type II diabetes. Acta Diabetol 2009;46:239-42
  13. Gocmen AY, Ozdemir L, Gumuslu S, Semiz E. Koroner Arter Hastalığı Olan Diyabetik ve Non diyabetik Hastalarda Paraoksonaz 1 Aktivitesive Lipid Peroksidasyonu Belirteç Düzeyleri Arasındaki İlişki. Turkiye Klinikleri J Endocrin 2010; 5: 74-80
  14. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc B